FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195328787> ?p ?o ?g. }

• W3195328787 endingPage "1801" @default.
• W3195328787 startingPage "1787" @default.
• W3195328787 abstract "// Taylor J. Chen 1 , Wa Du 1 , Jacob J. Junco 2 , Cory Seth Bridges 1 , Ye Shen 1 , Monica Puppi 1 , Karen R. Rabin 2 and H. Daniel Lacorazza 1 1 Department of Pathology &#x0026; Immunology, Baylor College of Medicine, Houston, TX, USA 2 Texas Children&#x2019;s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA Correspondence to: H. Daniel Lacorazza, email: hdl@bcm.edu Keywords: T-ALL; MAP2K7; 5z-7-oxozeaenol Received: June 30, 2021     Accepted: July 28, 2021     Published: August 31, 2021 Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive pediatric leukemia with a worse prognosis than most frequent B-cell ALL due to a high incidence of treatment failures and relapse. Our previous work showed that loss of the pioneer factor KLF4 in a NOTCH1-induced T-ALL mouse model accelerated the development of leukemia through expansion of leukemia-initiating cells and activation of the MAP2K7 pathway. Similarly, epigenetic silencing of the KLF4 gene in children with T-ALL was associated with MAP2K7 activation. Here, we showed the small molecule 5Z-7-oxozeaenol (5Z7O) induces dose-dependent cytotoxicity in a panel of T-ALL cell lines mainly through inhibition of the MAP2K7-JNK pathway, which further validates MAP2K7 as a therapeutic target. Mechanistically, 5Z7O-mediated apoptosis was caused by the downregulation of regulators of the G2/M checkpoint and the inhibition of survival pathways. The anti-leukemic capacity of 5Z7O was evaluated using leukemic cells from two mouse models of T-ALL and patient-derived xenograft cells generated using lymphoblasts from pediatric T-ALL patients. Finally, a combination of 5Z7O with dexamethasone, a drug used in frontline therapy, showed synergistic induction of cytotoxicity. In sum, we report here that MAP2K7 inhibition thwarts survival mechanisms in T-ALL cells and warrants future pre-clinical studies for high-risk and relapsed patients." @default.
• W3195328787 created "2021-08-30" @default.
• W3195328787 creator A5009302062 @default.
• W3195328787 creator A5010578315 @default.
• W3195328787 creator A5019389611 @default.
• W3195328787 creator A5037347309 @default.
• W3195328787 creator A5042776973 @default.
• W3195328787 creator A5059733552 @default.
• W3195328787 creator A5077906643 @default.
• W3195328787 creator A5082926384 @default.
• W3195328787 date "2021-08-31" @default.
• W3195328787 modified "2023-10-17" @default.
• W3195328787 title "Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia" @default.
• W3195328787 cites W1968829231 @default.
• W3195328787 cites W1982987975 @default.
• W3195328787 cites W1997110892 @default.
• W3195328787 cites W1999662762 @default.
• W3195328787 cites W2000571234 @default.
• W3195328787 cites W2003013566 @default.
• W3195328787 cites W2012034410 @default.
• W3195328787 cites W2016833582 @default.
• W3195328787 cites W2020476607 @default.
• W3195328787 cites W2031919933 @default.
• W3195328787 cites W2037522752 @default.
• W3195328787 cites W2038331455 @default.
• W3195328787 cites W2071268727 @default.
• W3195328787 cites W2077515371 @default.
• W3195328787 cites W2077945404 @default.
• W3195328787 cites W2084454660 @default.
• W3195328787 cites W2087369559 @default.
• W3195328787 cites W2094395262 @default.
• W3195328787 cites W2096931514 @default.
• W3195328787 cites W2105435030 @default.
• W3195328787 cites W2114293083 @default.
• W3195328787 cites W2116254970 @default.
• W3195328787 cites W2116274406 @default.
• W3195328787 cites W2125048552 @default.
• W3195328787 cites W2141869972 @default.
• W3195328787 cites W2146512944 @default.
• W3195328787 cites W2170444099 @default.
• W3195328787 cites W2225269395 @default.
• W3195328787 cites W2327179721 @default.
• W3195328787 cites W2336582847 @default.
• W3195328787 cites W2339215362 @default.
• W3195328787 cites W2343364134 @default.
• W3195328787 cites W2406250479 @default.
• W3195328787 cites W2419408332 @default.
• W3195328787 cites W2553011900 @default.
• W3195328787 cites W2590406062 @default.
• W3195328787 cites W2594188492 @default.
• W3195328787 cites W2604662815 @default.
• W3195328787 cites W2610571465 @default.
• W3195328787 cites W2735451781 @default.
• W3195328787 cites W2750580996 @default.
• W3195328787 cites W2755381750 @default.
• W3195328787 cites W2765567550 @default.
• W3195328787 cites W2916389916 @default.
• W3195328787 cites W2918708984 @default.
• W3195328787 cites W2944727022 @default.
• W3195328787 cites W2976461335 @default.
• W3195328787 cites W3019771578 @default.
• W3195328787 cites W3048853605 @default.
• W3195328787 cites W3085965519 @default.
• W3195328787 doi "https://doi.org/10.18632/oncotarget.28040" @default.
• W3195328787 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8416565" @default.
• W3195328787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34504651" @default.
• W3195328787 hasPublicationYear "2021" @default.
• W3195328787 type Work @default.
• W3195328787 sameAs 3195328787 @default.
• W3195328787 citedByCount "3" @default.
• W3195328787 countsByYear W31953287872022 @default.
• W3195328787 countsByYear W31953287872023 @default.
• W3195328787 crossrefType "journal-article" @default.
• W3195328787 hasAuthorship W3195328787A5009302062 @default.
• W3195328787 hasAuthorship W3195328787A5010578315 @default.
• W3195328787 hasAuthorship W3195328787A5019389611 @default.
• W3195328787 hasAuthorship W3195328787A5037347309 @default.
• W3195328787 hasAuthorship W3195328787A5042776973 @default.
• W3195328787 hasAuthorship W3195328787A5059733552 @default.
• W3195328787 hasAuthorship W3195328787A5077906643 @default.
• W3195328787 hasAuthorship W3195328787A5082926384 @default.
• W3195328787 hasBestOaLocation W31953287871 @default.
• W3195328787 hasConcept C104317684 @default.
• W3195328787 hasConcept C107459253 @default.
• W3195328787 hasConcept C143998085 @default.
• W3195328787 hasConcept C145103041 @default.
• W3195328787 hasConcept C190283241 @default.
• W3195328787 hasConcept C203014093 @default.
• W3195328787 hasConcept C2778265714 @default.
• W3195328787 hasConcept C2778461978 @default.
• W3195328787 hasConcept C2909962599 @default.
• W3195328787 hasConcept C502942594 @default.
• W3195328787 hasConcept C54355233 @default.
• W3195328787 hasConcept C71924100 @default.
• W3195328787 hasConcept C86803240 @default.
• W3195328787 hasConceptScore W3195328787C104317684 @default.
• W3195328787 hasConceptScore W3195328787C107459253 @default.
• W3195328787 hasConceptScore W3195328787C143998085 @default.

• next